Navigation Links
Soligenix to Present at 9th Annual Biotech Showcase Conference
Date:1/6/2017

PRINCETON, N.J., Jan. 6, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present a company overview at the 9th Annual Biotech Showcase Conference on Wednesday, January 11, 2017 at 9:30 a.m. PST. The conference will be held at the Hilton San Francisco Union Square, San Francisco, CA. For more information on the conference, please go to https://ebdgroup.knect365.com/biotech-showcase/.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).

Our Vaccines/BioDefense business segment includes active development programs for RiVax™, our ricin toxin vaccine candidate, OrbeShield®, our GI acute radiation syndrome therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  Currently, this business segment is supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K.  Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/soligenix-to-present-at-9th-annual-biotech-showcase-conference-300386537.html


'/>"/>
SOURCE Soligenix, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
2. Soligenix Announces Investor Webcast Event: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
3. Soligenix to Present at Source Capital Groups 2016 Disruptive Growth & Healthcare Conference
4. Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
5. Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results
6. Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
7. Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
8. Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
9. Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board
10. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
11. Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2019)... ... 2019 , ... Modality Solutions, an Inc. Verified Company, ... network experts, and experienced integrated staffing professionals. , Upon receiving Modality ... program, Inc. editors independently reviewed the Houston-based cold chain management company to validate ...
(Date:2/27/2019)... SEABROOK, N.H. (PRWEB) , ... February 26, 2019 ... ... system integrator of custom industrial automation and IT solutions with 140 employees on ... recently earned his professional engineer’s license in the State of New Hampshire. Sandmaier, ...
(Date:2/22/2019)... , ... February 20, 2019 , ... Superior Controls, ... IT solutions with 140 employees on both the east and west coasts, today announced ... Manager working out of the company’s Seabrook, New Hampshire office. In his new ...
(Date:2/16/2019)... TORONTO (PRWEB) , ... February 14, 2019 , ... ... data visualization, analytics, and knowledge sharing capability that also provides the flexibility for ... and play” functionality. It also provides a shared workbench to conduct quick analytics ...
Breaking Biology Technology:
(Date:3/13/2019)... ... ... Sleep problems constitute a global epidemic that threatens health and quality of ... billion people worldwide suffer from sleep apnea - a condition that occurs when ... go undiagnosed. Today, Beddr , the sleep health technology startup, announced its participation ...
(Date:3/11/2019)... ... March 11, 2019 , ... A new report published by the ... to previous generations; 77% of those aged 18 to 35 already have or are ... those aged 55 and older.(1) Among all LGBTQ prospective parents, 41% are considering assisted ...
(Date:3/9/2019)... ... , ... A firm believer in causes greater than all of us, Makers ... will help fund not only research to find a cure, but services that provide ... on the lookout for ways to make a difference. When The Leukemia & Lymphoma ...
Breaking Biology News(10 mins):